Patent No. 600803 Disclosed is the use of rhCC 10 for the manufacture of a medicament for the therapeutic or prophylactic treatment of rhinosinusitis, nasal polyps, bacterial sinus infection and sinus pain, and formulated to be administered to a mucosal membrane other than nasally, wherein rhCCI0 has a concentration of not more than 2 mg/mL.